Refine
Year of publication
Document Type
- Article (5125)
- Doctoral Thesis (1468)
- Part of Periodical (210)
- Conference Proceeding (164)
- Preprint (159)
- Book (85)
- Contribution to a Periodical (60)
- Review (38)
- Working Paper (22)
- Part of a Book (16)
Language
Is part of the Bibliography
- no (7367) (remove)
Keywords
- inflammation (80)
- COVID-19 (58)
- SARS-CoV-2 (48)
- apoptosis (38)
- glioblastoma (38)
- Inflammation (37)
- cancer (37)
- breast cancer (34)
- autophagy (29)
- Apoptosis (25)
Institute
- Medizin (7367) (remove)
Novel therapies for lung cancer are being explored nowadays with local therapies being the tip of the arrow. Intratumoral chemotherapy administration and local microwave ablation have been investigated in several studies. It has been previously proposed that lipiodol has the ability to modify the microenvironment matrix. In our current study we investigated this theory in BALBC mice. In total 160 BALBC mice were divided in eight groups: a) control, b) cisplatin, c) microwave, d) microwave and lipiodol, e) cisplatin and lipiodol, f) microwave and cisplatin, g) lipiodol and h) lipiodol, cisplatin and microwave. Lewis lung carcinoma cell lines (106) were injected into the right back leg of each mouse. After the 8th day, when the tumor volume was about 100mm3 the therapy application was initiated, once per week for four weeks. Magnetic resonance imaging was performed for each tumor when a mouse died or when sacrificed if they were still alive by the end of the experiment (8-Canal multifunctional spool; NORAS MRI products, Gmbh, Germany). Imaging and survival revealed efficient tumor apoptosis for the groups b,c,d,e and f. However; severe toxicity was observed in group h and no follow up was available for this group after the second week of therapy administration. Lipiodol in its current form does assist in a more efficient way the distribution of cisplatin, as the microwave apoptotic effect. Future modification of lipiodol might provide a more efficient method of therapy enhancement. Combination of drug and microwave ablation is possible and has an efficient apoptotic effect.
Background: The phagocytic enzyme myeloperoxidase (MPO) acts as a front-line defender against microorganisms. However, increased MPO levels have been found to be associated with complex and calcified atherosclerotic lesions and incident cardiovascular disease. Therefore, this study aimed to investigate a predictive role of MPO, a biomarker of inflammation and oxidative stress, for total and cardiovascular mortality in patients referred to coronary angiography.
Methods and results: MPO plasma concentrations along with eight MPO polymorphisms were determined in 3036 participants of the Ludwigshafen Risk and Cardiovascular Health study (median follow-up 7.75 years). MPO concentrations were positively associated with age, diabetes, smoking, markers of systemic inflammation (interleukin-6, fibrinogen, C-reactive protein, serum amyloid A) and vascular damage (vascular cellular adhesion molecule-1 and intercellular adhesion molecule-1) but negatively associated with HDL-cholesterol and apolipoprotein A-I. After adjustment for cardiovascular risk factors MPO concentrations in the highest versus the lowest quartile were associated with a 1.34-fold risk (95% CI: 1.09–1.67) for total mortality. In the adjusted model the hazard ratio for cardiovascular mortality in the highest MPO quartile was 1.42 (95% CI: 1.07–1.88). Five MPO polymorphisms were positively associated with MPO concentrations but not with mortality. Using Mendelian randomization, we did not obtain evidence for a causal association of MPO with either total or cardiovascular mortality.
Conclusions: MPO concentrations but not genetic variants at the MPO locus are independently associated with risk for total and cardiovascular mortality in coronary artery disease patients.
Glioblastoma multiforme (GBM) is a deadly primary brain malignancy. Glioblastoma stem cells (GSC), which have the ability to self-renew and differentiate into tumor lineages, are believed to cause tumor recurrence due to their resistance to current therapies. A subset of GSCs is marked by cell surface expression of CD133, a glycosylated pentaspan transmembrane protein. The study of CD133-expressing GSCs has been limited by the relative paucity of genetic tools that specifically target them. Here, we present CD133-LV, a lentiviral vector presenting a single chain antibody against CD133 on its envelope, as a vehicle for the selective transduction of CD133-expressing GSCs. We show that CD133-LV selectively transduces CD133+ human GSCs in dose-dependent manner and that transduced cells maintain their stem-like properties. The transduction efficiency of CD133-LV is reduced by an antibody that recognizes the same epitope on CD133 as the viral envelope and by shRNA-mediated knockdown of CD133. Conversely, the rate of transduction by CD133-LV is augmented by overexpression of CD133 in primary human GBM cultures. CD133-LV selectively transduces CD133-expressing cells in intracranial human GBM xenografts in NOD.SCID mice, but spares normal mouse brain tissue, neurons derived from human embryonic stem cells and primary human astrocytes. Our findings indicate that CD133-LV represents a novel tool for the selective genetic manipulation of CD133-expressing GSCs, and can be used to answer important questions about how these cells contribute to tumor biology and therapy resistance.
Escherichia coli α-hemolysin (HlyA) is a pore-forming protein of 110 kDa belonging to the family of RTX toxins. A hydrophobic region between the amino acid residues 238 and 410 in the N-terminal half of HlyA has previously been suggested to form hydrophobic and/or amphipathic α-helices and has been shown to be important for hemolytic activity and pore formation in biological and artificial membranes. The structure of the HlyA transmembrane channel is, however, largely unknown. For further investigation of the channel structure, we deleted in HlyA different stretches of amino acids that could form amphipathic β-strands according to secondary structure predictions (residues 71–110, 158–167, 180–203, and 264–286). These deletions resulted in HlyA mutants with strongly reduced hemolytic activity. Lipid bilayer measurements demonstrated that HlyAΔ71–110 and HlyAΔ264–286 formed channels with much smaller single-channel conductance than wildtype HlyA, whereas their channel-forming activity was virtually as high as that of the wildtype toxin. HlyAΔ158–167 and HlyAΔ180–203 were unable to form defined channels in lipid bilayers. Calculations based on the single-channel data indicated that the channels generated by HlyAΔ71–110 and HlyAΔ264–286 had a smaller size (diameter about 1.4 to 1.8 nm) than wildtype HlyA channels (diameter about 2.0 to 2.6 nm), suggesting that in these mutants part of the channel-forming domain was removed. Osmotic protection experiments with erythrocytes confirmed that HlyA, HlyAΔ71–110, and HlyAΔ264–286 form defined transmembrane pores and suggested channel diameters that largely agreed with those estimated from the single-channel data. Taken together, these results suggest that the channel-forming domain of HlyA might contain β-strands, possibly in addition to α-helical structures.
Previously we reported modulation of endothelial prostacyclin and interleukin-8 production, cyclooxygenase-2 expression and vasorelaxation by oleoyl-lysophosphatidylcholine (LPC 18:1). In the present study, we examined the impact of this LPC on nitric oxide (NO) bioavailability in vascular endothelial EA.hy926 cells. Basal NO formation in these cells was decreased by LPC 18:1. This was accompanied with a partial disruption of the active endothelial nitric oxide synthase (eNOS)-dimer, leading to eNOS uncoupling and increased formation of reactive oxygen species (ROS). The LPC 18:1-induced ROS formation was attenuated by the superoxide scavenger Tiron, as well as by the pharmacological inhibitors of eNOS, NADPH oxidases, flavin-containing enzymes and superoxide dismutase (SOD). Intracellular ROS-formation was most prominent in mitochondria, less pronounced in cytosol and undetectable in endoplasmic reticulum. Importantly, Tiron completely prevented the LPC 18:1-induced decrease in NO bioavailability in EA.hy926 cells. The importance of the discovered findings for more in vivo like situations was analyzed by organ bath experiments in mouse aortic rings. LPC 18:1 attenuated the acetylcholine-induced, endothelium dependent vasorelaxation and massively decreased NO bioavailability. We conclude that LPC 18:1 induces eNOS uncoupling and unspecific superoxide production. This results in NO scavenging by ROS, a limited endothelial NO bioavailability and impaired vascular function.
Myotonic dystrophy type 1 (DM1) lacks non-invasive and easy to measure biomarkers, still largely relying on semi-quantitative tests for diagnostic and prognostic purposes. Muscle biopsies provide valuable data, but their use is limited by their invasiveness. microRNA (miRNAs) are small non-coding RNAs regulating gene expression that are also present in biological fluids and may serve as diseases biomarkers. Thus, we tested plasma miRNAs in the blood of 36 DM1 patients and 36 controls. First, a wide miRNA panel was profiled in a patient subset, followed by validation using all recruited subjects. We identified a signature of nine deregulated miRNAs in DM1 patients: eight miRNAs were increased (miR-133a, miR-193b, miR-191, miR-140-3p, miR-454, miR-574, miR-885-5p, miR-886-3p) and one (miR-27b) was decreased. Next, the levels of these miRNAs were used to calculate a "DM1-miRNAs score". We found that both miR-133a levels and DM1-miRNAs score discriminated DM1 from controls significantly and Receiver-Operator Characteristic curves displayed an area under the curve of 0.94 and 0.97, respectively. Interestingly, both miR-133a levels and DM1-miRNAs score displayed an inverse correlation with skeletal muscle strength and displayed higher values in more compromised patients. In conclusion, we identified a characteristic plasma miRNA signature of DM1. Although preliminary, this study indicates miRNAs as potential DM1 humoral biomarkers.
Bei Knochendefekten kritischer Größe ist es notwendig, den Knochen bei der Heilung zu unterstützen. Der derzeitige Goldstandard bei der Behandlung von critical size defects ist die Entnahme von autologem Knochen aus dem Beckenkamm, dies ist jedoch mit Nachteilen wie Entnahmemorbidität und Limitierung der entnehmbaren Menge vergesellschaftet. Das Knochen tissue engineering, bei welchem regenerative Zellen mit einem Knochenersatzmaterial kombiniert werden, könnte eine vielversprechende Alternative sein. Stromale Knochenmarkzellen, die Osteoblasten differenzieren können, und endotheliale Vorläuferzellen, die die Vaskularisierung der Defektzone unterstützen, zeigten sich effektiv in tierexperimentellen Studien; jedoch müssen diese Zellen vor Verwendung über einen längeren Zeitraum in Kultur expandiert werden. Dies kann jedoch zu einer Akkumulation genetischer Schäden und möglicherweise zu einer Entartung der transplantierten Zellen führen. Bone marrow mononuclear cells (BMC) stellen eine interessante Alternative dar, sie können innerhalb weniger Stunden isoliert und dem Patienten zurückgegeben werden. Ziel dieser Arbeit war daher, die Adhäsion und funktionelle Aspekte von BMC auf drei verschiedenen Knochenersatzmaterialien zu analysieren.
Im ersten Versuchsteil wurde untersucht, ob es möglich ist, BMC auf einem β-Tricalciumphosphat (β-TCP)-Scaffold auszusäen, und ob eine Beschichtung des Scaffolds eine positive Auswirkung auf die BMC-Adhäsion und Aktivität hat. Hierbei wurde eine Beschichtung mit humanem Plasma (FFP) und Fibronektin gegen eine Kontrolle verglichen. Es konnte gezeigt werden, dass BMC auf unbeschichtetem β-TCP adhärieren und dass eine Vorbeschichtung des Scaffolds mit Fibronektin oder mit FFP zu keiner weiteren Verbesserung der initialen Adhäsion führt. FACS-Analysen zeigten, dass der Prozentsatz der auf dem Material adhärierenden Fraktionen regenerativer Zellen dem Prozentsatz der in der Kontrolle enthaltenen regenerativen Zellen entspricht. Überdies konnte eine endotheliale Differenzierung der ausgesäten BMC beobachtet werden. Die Anzahl adhärierender BMC war zum ersten Messpunkt an Tag zwei unabhängig von der Vorbeschichtung am höchsten. Interessanterweise war die Zahl der adhärierenden BMC auf unbeschichtetem Material signifikant gegenüber den beschichteten Materialien erhöht.
Basierend auf der Beobachtung, dass eine Vorbeschichtung der Trägersubstanz nicht zu einer Verbesserung der BMC-Adhäsion auf dem Gerüststoff führt, wurden im zweiten Versuchsteil unbeschichtete Gerüststoffe miteinander verglichen. Für diese Arbeit wurden drei aus verschiedenen Klassen der Knochenersatzmaterialien stammende Scaffolds gewählt. ChronOs® als Vertreter der β-TCPs, Cerabone®, eine verarbeitete bovine Knochenmatrix, und Demineralized Bone Matrix (DBM), ein sterilisiertes humanes Knochentransplantat. Die Untersuchungen ergaben signifikante Unterschiede in der Aussaateffizienz der Zellen auf den Materialien und der Zellaktivität im Verlauf über 21 Tage. DBM zeigte hier im Materialvergleich die besten Ergebnisse. In unserem Versuch zeigte sich die Menge der absorbierten Flüssigkeit im Verhältnis zur Materialmenge bei DBM signifikant erhöht gegenüber den beiden anderen Materialien. Zudem konnte mittels HE- und Kern-Färbung (DAPI) der Nachweis erbracht werden, dass sich Zellen tief im Inneren des Materials anlagern. MTT-Tests zeigten an Tag 14 eine signifikant erhöhte metabolische Aktivität auf DBM gegenüber Cerabone® und an Tag 21 gegenüber beiden Vergleichsmatrices. Wir konnten auf allen Materialien an Tag 2 eine signifikant erhöhte VEGF-Produktion feststellen. Mittels Real-Time-PCR ließ sich eine VEGF-Genexpression in BMC auf allen Materialien bis Tag 14 und auf DBM über die kompletten 21 Tage nachweisen. Die Genexpression von vWF konnte ebenfalls auf allen Materialien über den gesamten Zeitraum nachgewiesen werden.
Zusammengefasst konnte durch diese Studie belegt werden, dass die initiale Adhärenz von BMC auf unbeschichtete Knochenersatzmaterialien generell hoch ist, aber signifikante materialspezifische Unterschiede in der Aussaateffizienz und nachfolgend der metabolischen Aktivität und der VEGFSynthese der BMC existieren. Humanes Knochenersatzmaterial zeigte sich in unserer Studie als überlegen. Daher sollte die Art des Knochenersatzmaterials für den künftigen klinischen Einsatz von BMC Berücksichtigung finden.
The neuroanatomical connectivity of cortical circuits is believed to follow certain rules, the exact origins of which are still poorly understood. In particular, numerous nonrandom features, such as common neighbor clustering, overrepresentation of reciprocal connectivity, and overrepresentation of certain triadic graph motifs have been experimentally observed in cortical slice data. Some of these data, particularly regarding bidirectional connectivity are seemingly contradictory, and the reasons for this are unclear. Here we present a simple static geometric network model with distance-dependent connectivity on a realistic scale that naturally gives rise to certain elements of these observed behaviors, and may provide plausible explanations for some of the conflicting findings. Specifically, investigation of the model shows that experimentally measured nonrandom effects, especially bidirectional connectivity, may depend sensitively on experimental parameters such as slice thickness and sampling area, suggesting potential explanations for the seemingly conflicting experimental results.
Background: High-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) is a treatment option for pediatric patients with relapsed nephroblastoma. We present long term results of 9 patients treated between 1993 and 2013 at our center.
Procedure: Reinduction therapy was carried out according to GPOH and SIOP recommendations. The conditioning regimen consisted of carboplatin (1 200 mg/m²), etoposide (800 mg/m² or 40 mg/kg) and melphalan (180 mg/m²). Purging of the grafts with immunomagnetic CD34 positive selection was performed in 5 patients.
Results: 8 of 9 Patients (90%) are alive without evidence of disease after a median follow-up of 8.5 years. Leukocyte engraftment occurred after a median of 10 days (range 8-12). Median numbers of 667/µl CD3+, 329/µl CD4+, 369/µl CD8+T cells and 949/µl B cells were reached after 180 days. No negative impact of CD34 selection was observed. No transplantation-related death occurred. Acute toxicity comprised mucositis III°-IV° in all and veno-occlusive disease in one patient. Long term effects probably related to treatment occurred in 3/7 evaluable patients and comprised hearing impairment, reduced renal phosphate reabsorption, mild creatinine elevation and hypothyroidism (n=1, each).
Conclusion: Thus, in our experience HDC with ASCR is an effective treatment of recurrent or refractory nephroblastoma with acceptable side effects. However, a randomized trial proving its efficiency with a high level of evidence is needed.